Skip to main content
Premium Trial:

Request an Annual Quote

Sirius Genomics Teams with UK Genomics Group

NEW YORK (GenomeWeb News) — Sirius Genomics will collaborate with a UK research group focused on human disease gene studies to develop the company’s pharmacogenomic test for patient response to a drug treatment for infection and sepsis.
 
Sirius said today that the United Kingdom Critical Care Genomics Group will help develop its test for responsiveness to recombinant actived Protein C, which is marketed by Eli Lilly under the name Xigris.
 
"The UKCCG group is conducting a large genomic association study looking at severe life-threatening infections and sepsis,” Sirius Genomics CEO Brad Popovich said in a statement. He added that the collaboration will allow the company to “significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled.”
 
Financial terms of the agreement were not disclosed.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.